Search results
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
Morningstar· 21 hours agoRegion (“DO”) has recently accepted the New Drug Application (“NDA”) for toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of adults with ...
Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting
FOX21 Colorado Springs· 22 hours agoFirst-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced colorectal cancer: Safety and efficacy results from a phase I study. First-in-class ...
Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
Zacks· 1 week agoXTX301 is Xilio’s tumor-activated IL-12, developed using the company’s proprietary tumor-activation...
Merck highlights progress on HIV, hypertension, cervical cancer drugs
WFMZ Eastern Pennsylvania and Western New Jersey· 6 hours agoWall Street met the news with approval as Merck’s stock traded up nearly 3% in morning trading while...
Insider Selling: BeiGene, Ltd. (NASDAQ:BGNE) CEO Sells 26,716 Shares of Stock
ETF DAILY NEWS· 2 weeks agoBeiGene, Ltd. (NASDAQ:BGNE – Get Free Report) CEO John Oyler sold 26,716 shares of the stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price ...
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
Zacks· 4 days agoFree Report) will report first-quarter 2024 results on Apr 25, before market open. In the last...
Mirae Asset Global Investments Co. Ltd. Trims Stock Position in Iovance Biotherapeutics, Inc....
ETF DAILY NEWS· 3 days agoLtd. trimmed its stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 3.4% during the fourth quarter, according to its most recent 13F filing with the Securities and ...
Zacks Research Analysts Lower Earnings Estimates for Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
ETF DAILY NEWS· 7 days agoIovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) – Analysts at Zacks Research cut their FY2024 earnings estimates for Iovance Biotherapeutics in a note issued to investors on Monday ...
Analysts Set BeiGene, Ltd. (NASDAQ:BGNE) PT at $251.70
ETF DAILY NEWS· 4 days agoBeiGene, Ltd. (NASDAQ:BGNE – Get Free Report) has been given an average recommendation of “Moderate Buy” by the nine ratings firms that are currently covering the stock, MarketBeat Ratings reports ...
BeiGene (NASDAQ:BGNE) Trading Down 2.4%
ETF DAILY NEWS· 5 days agoBeiGene, Ltd. (NASDAQ:BGNE – Get Free Report)’s stock price dropped 2.4% during trading on Friday . The company traded as low as $126.97 and last traded at $128.77. Approximately ...
